Press Releases

« Back

Tetraphase Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call

August 01, 2019

WATERTOWN, Mass.--(BUSINESS WIRE)--Aug. 1, 2019-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will host a conference call at 4:30 p.m. ET on Thursday, August 8, 2019 to discuss the Company’s second quarter 2019 financial results and provide a general corporate update.

The conference call may be accessed by dialing 844-831-4023 (U.S. and Canada) or 731-256-5215 (international) and entering conference ID number 2336585. A live audio webcast of the conference call will be available online from the “Investors – Events & Presentations” section of the Tetraphase website at

A replay of the conference call will be available from 7:30 p.m. ET on Thursday, August 8, 2019, through 7:30 p.m. ET on Thursday, August 15, 2019 by dialing 855-859-2056 (U.S. and Canada) and 404-537-3406 for (international) callers. The conference ID number is 2336585. A replay of the webcast will be available by visiting Tetraphase’s website.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using its proprietary chemistry technology to create novel tetracyclines for serious and life-threatening conditions, including infections caused by many of the multidrug-resistant bacteria highlighted as urgent public health threats by the World Health Organization and the Centers for Disease Control and Prevention. The Company has created more than 3,000 novel tetracycline compounds using its proprietary technology platform. Tetraphase's lead product XERAVA™ is approved for the treatment of complicated intra-abdominal infections by the U.S. Food and Drug Administration and the European Medicines Agency. The Company’s pipeline also includes TP-271 and TP-6076, which are Phase 2 ready, and TP-2846, which is in preclinical testing for acute myeloid leukemia. The Company intends to outlicense its pipeline candidates. Please visit for more company information.

Source: Tetraphase Pharmaceuticals, Inc.

Media and Investor Contact:
Argot Partners
Maeve Conneighton

Contact Us

Tetraphase Pharmaceuticals, 480 Arsenal Way, Suite 110, Watertown, MA 02472

Tel 617-715-3600 | Fax 617-926-3557 | CONTACT AND MEDICAL INFORMATION

Forward Looking Statements | Terms of Use | Privacy Policy

Copyright © Tetraphase Pharmaceuticals       All rights reserved.


Please enter a valid email address.


Please enter a valid email address.


Share information about Tetraphase


Thank you! Your email has been sent.